SRR608598
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.516
- IL6_JAK_STAT3_SIGNALING+0.488
- INTERFERON_GAMMA_RESPONSE+0.482
- INTERFERON_ALPHA_RESPONSE+0.474
- INFLAMMATORY_RESPONSE+0.460
- ANGIOGENESIS+0.428
- COAGULATION+0.358
- COMPLEMENT+0.336
- IL2_STAT5_SIGNALING+0.328
- KRAS_SIGNALING_UP+0.325
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.666
- MYC_TARGETS_V2-0.558
- DNA_REPAIR-0.501
- MYC_TARGETS_V1-0.473
- UNFOLDED_PROTEIN_RESPONSE-0.426
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.424
- ADIPOGENESIS-0.412
- FATTY_ACID_METABOLISM-0.366
- MTORC1_SIGNALING-0.336
- GLYCOLYSIS-0.306
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR602131 | GTEX | — | 0.966 |
| 2 | SRR1330546 | GTEX | — | 0.962 |
| 3 | SRR607445 | GTEX | — | 0.961 |
| 4 | SRR818270 | GTEX | — | 0.956 |
| 5 | SRR1335446 | GTEX | — | 0.956 |
| 6 | SRR599510 | GTEX | — | 0.951 |
| 7 | SRR615020 | GTEX | — | 0.950 |
| 8 | SRR821602 | GTEX | — | 0.948 |
| 9 | SRR1474795 | GTEX | — | 0.946 |
| 10 | SRR1361795 | GTEX | — | 0.946 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.516 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.488 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.482 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.474 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.428 | Remibrutinib | — uncovered |
| COAGULATION | 0.358 | Binimetinib | — uncovered |
| COMPLEMENT | 0.336 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.328 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.325 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.278 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.275 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.234 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.153 | Inavolisib | — uncovered |
| APOPTOSIS | 0.127 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.124 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.087 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.075 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.055 | Inavolisib | — uncovered |